title: Adjuvant strategies for resectable pancreatic cancer: have we made progress?
abstract: Substantial controversy remains regarding the optimal adjuvant treatment for patients with resectable pancreatic adenocarcinoma. Despite improvements in radiation techniques, systemic therapies, and incorporation of targeted agents, the 5-year survival rates for early stage patients remains less than 25% and the optimal adjuvant treatment approach remains unclear. Here we summarize the data presented at the 2012 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium regarding controversial issues surrounding the role, timing, and selection of patients for adjuvant chemoradiation strategies following curative resection for pancreatic adenocarcinoma. (Abstracts #301, #333, and #206).
authors.affiliation: Department of Radiation Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36532, USA. srusso@usouthal.edu
authors.forename: Suzanne
authors.initials: S
authors.lastname: Russo
authors.forename: Anshu K
authors.initials: AK
authors.lastname: Jain
authors.forename: Muhammad Wasif
authors.initials: MW
authors.lastname: Saif
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000601:surgery* / Q000628:therapy*; D059186:Chemoradiotherapy, Adjuvant / Q000639:trends*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000601:surgery* / Q000628:therapy*